investing into
future medicines

Our mission is to support innovations that improve patients‘ lifes.
We engage early and stand alongside founders and researchers to bring outstanding ideas to the market.
We invest in highly differentiated technical solutions that can become future standards of care.

News

Team

Aleksei Zeifman, PhD, MBA

Investment Manager

Alex holds PhD degree in computational chemistry and MBA from Mannheim Business School. Alex brings more than 10 years of experience in the biotech space, being a co-founder of drug development startup himself and then moving to the VC side. He successfully invested in Biotech and Medtech startups from a VC fund RBV Capital and from CVC arm of tier 1 reinsurance company SCOR.

Nicholas H. Vetter, MBA

Investment Committee

Nick holds an MBA from SDA Bocconi school of management and studied Human Physiology at the University of Colorado. He is currently CEO of OncoBeta, a Radiation Oncology company, and acts as Board member / Board observer in different companies in healthcare. He is part of the 3rd generation of ownership in Vetter Pharma.

Timo Köhler, MBA

VP Finance

Timo holds a Diploma in Business Administration from DHBW Mannheim / Bachelor degree from Open University London as well as a MBA from WWU Muenster (CUR). He has gained broad experience in finance management throughout roles within different international companies including Merck and Vetter Pharma.

Carla Benichou, MSc

Investment Analyst

Carla graduated in Business Administration from ESADE and holds an MSc in Applied Neurosciences from King’s College London. She has 4 years of experience supporting innovative technology startups through her roles in the consulting firm Gartner, the biotech startup accelerator BaseLaunch and the impact-driven VC fund LBS. Her responsibilities included the search for new investment opportunities, the analysis of companies prior to investment and the support of start-ups’ growth and financing efforts.

Portfolio

Asgard Therapeutics (Lund, Sweden) is a private biotech company pioneering direct in vivo cell reprogramming for cancer immunotherapy.

Valink (London, GB) uses protein building blocks to construct complex bispecific and multispecific biologics for high unmet need disease areas.

Tune Therapeutics (Durham, NC, US) is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine.

Immusoft (Seattle, WA, US) is a clinical-stage cell therapy company focused on developing novel therapies for rare diseases using a sustained delivery of protein therapeutics from a patient’s own cells.

Contact

RV Invest GmbH
Banneggstrasse 57
88214 Ravensburg
Germany

investing into future medicines